Anna V. Senina

Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants

Christopher A. Eide, Matthew S. Zabriskie, Samantha L. Savage et al. · Cancer Cell · 2019 · 239 citations · Full text

Allosteric Inhibitor Asciminib, Medicine, Immunology +8

Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia

Anna M. Eiring, Brent D. G. Page, Ira L. Kraft et al. · Leukemia · 2014 · 132 citations · Full text

Hematological Malignancy, Medicine, Mixed-phenotype Acute Leukemia +8

A Small-Molecule Inhibitor of PIM Kinases as a Potential Treatment for Urothelial Carcinomas

Jason M. Foulks, Kent J. Carpenter, Bai Luo et al. · Neoplasia · 2014 · 89 citations · Full text

Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth

K. Mark Parnell, Jason M. Foulks, Rebecca N. Nix et al. · Molecular Cancer Therapeutics · 2013 · 69 citations

SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia

Dongqing Yan, Anca Franzini, Anthony D. Pomicter et al. · Blood Cancer Discovery · 2021 · 57 citations · Full text